Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria: Insights from the Society of Infectious Diseases Pharmacists

Aerosolized delivery of antimicrobial agents is an attractive option for management of pulmonary infections, as this is an ideal method of providing high local drug concentrations while minimizing systemic exposure. With the paucity of consensus regarding the safety, efficacy, and means with which t...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2010-06, Vol.30 (6), p.562-584
Main Authors: LE, Jennifer, DODDS ASHLEY, Elizabeth, VANDENBUSSCHE, Heather L, WOOD, G. Christopher, NEUHAUSER, Melinda M, BROWN, Jack, GENTRY, Chris, KLEPSER, Michael E, MARR, Ann Marie, SCHILLER, Daryl, SCHWIESOW, Joshua N, TICE, Sally
Format: Article
Language:English
Subjects:
Administration, Inhalation
Aerosols - administration & dosage
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - adverse effects
Biological and medical sciences
Consensus
Drugs, Investigational - administration & dosage
Humans
Medical sciences
Nebulizers and Vaporizers
Patient Education as Topic
Pharmacology. Drug treatments
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - prevention & control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aerosolized delivery of antimicrobial agents is an attractive option for management of pulmonary infections, as this is an ideal method of providing high local drug concentrations while minimizing systemic exposure. With the paucity of consensus regarding the safety, efficacy, and means with which to use aerosolized antimicrobials, a task force was created by the Society of Infectious Diseases Pharmacists to critically review and evaluate the literature on the use of aerosolized antiinfective agents. This article summarizes key findings and statements for preventing or treating a variety of infectious diseases, including cystic fibrosis, bronchiecstasis, hospital-acquired pneumonia, fungal infections, nontuberculosis mycobacterial infection, and Pneumocystis jiroveci pneumonia. Our intention was to provide guidance for clinicians on the use of aerosolized antibiotics through evidence-based pharmacotherapy. Further research with well-designed clinical trials is necessary to elucidate the optimal dosage and duration of therapy and, of equal importance, to appreciate the true risks associated with the use of aerosolized delivery systems.
ISSN:0277-0008
1875-9114
DOI:10.1592/phco.30.6.562